Small Molecules News and Research

RSS

Publication validates company's structure-based approach for addressing undruggable targets

Emerald BioStructures (formerly deCODE biostructures) announced today a publication in the December 27, 2009 advance online issue of Nature Biotechnology, detailing the application of structure-based drug design (SBDD) to engineer new allosteric small molecule modulators of the enzyme phosphodiesterase-4 (PDE4), with reduced side effects.

28 Dec 2009

Response Biomedical receives USPTO Notice of Allowance for its “Sensitive Immunochromatographic Assay”

Response Biomedical Corporation announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a continuation of the patent entitled “Sensitive Immunochromatographic Assay”. This patent covers key aspects of Response Biomedical’s lateral flow immunoassays with the proprietary RAMP® testing platform.

21 Dec 2009

Modulating PN aggregase pathway may offer hope for Alzheimer’s disease

Proteostasis Therapeutics announced today that modulating a key Proteostasis Network (PN) pathway may offer a novel approach to Alzheimer’s disease, a finding that was published in the journal Cell by its scientific founders Andrew Dillin, Ph.D., and Jeffery Kelly, Ph.D. The publication describes how regulation of an aggregase pathway reduced the neurodegenerative effects of beta amyloid aggregates that are a hallmark of the disease.

16 Dec 2009

Molecular Partners closes its CHF 46 million Series B equity investment round

Molecular Partners AG, a pioneer in the development of DARPins as next generation protein therapeutics, has announced the closing of its Series B equity investment round securing CHF 46 million (€ 30 million, $ 45 million).

15 Dec 2009

Winners of the 2010 ASBMB-Merck Award

James A. Wells, professor and chairman of the department pharmaceutical chemistry at the University of California, San Francisco, and director of UCSF's small molecule discovery center, has been named the winner of the 2010 American Society for Biochemistry and Molecular Biology-Merck Award for his pioneering studies in the field of protein engineering.

11 Dec 2009

Discovery of new compounds may dispel cravings of methamphetamine and cocaine addiction

Sarah Steele and Langtian "Ren" Yuan were both self-admittedly inexperienced Duke freshmen in the spring of 2006. But then they followed helpful directions of an assistant chemistry professor, added their own patience and ingenuity, and ended up identifying compounds that might allay the powerful cravings of methamphetamine and cocaine addiction.

9 Dec 2009

TMZ and small molecule combination appears to lower tumor resistance

University of Florida researchers have found a way to use just a fraction of the normal dosage of a highly toxic, debilitating chemotherapy drug to achieve even better results against colon cancer cells.

9 Dec 2009

Study: Genetic variations in miRNA pathway may be used to predict secondary tumor in head and neck cancer patients

Eighteen single-point genetic variations indicate risk of recurrence for early-stage head and neck cancer patients and their likelihood of developing a second type of cancer, researchers at The University of Texas M. D. Anderson Cancer Center reported at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference.

8 Dec 2009

SU2C awards $9.68 million to support high-risk cancer research

Stand Up To Cancer (SU2C) announced today that it is awarding $9.68 million to support high-risk/high-reward cancer research conducted by 13 young scientists.

7 Dec 2009

TGen scientists win $1,000 prize for best scientific paper presented at BIBM09

A team of scientists at the Translational Genomics Research Institute (TGen) won a $1,000 prize for best scientific paper presented at BIBM09, a premier bioinformatics and biomedicine conference.

3 Dec 2009

Galapagos' multiple milestone achievement triggers cash payment of EUR 10.2 million

Galapagos NV announced today achievement of multiple milestones under its alliance agreement in rheumatoid arthritis. The milestones trigger a cash payment of EUR 10.2 million to Galapagos.

3 Dec 2009

New technology developed to rapidly identify compounds for the treatment of heart failure

Research conducted by University of Minnesota scientists, in collaboration with Celladon Corporation, has led to the invention of technology to more rapidly identify compounds for the treatment of heart failure.

24 Nov 2009

ScinoPharm receives Potent Compound Safety Certification from SafeBridge Consultants

ScinoPharm, a leading global supplier of active pharmaceutical ingredients (APIs), announced that its Tainan facility has received the Potent Compound Safety Certification from SafeBridge(R) Consultants, Inc.

20 Nov 2009

Unique life science-focused application for social media site launched

Sigma-Aldrich® today announced the launch of a unique life science-focused application for the social media site, Facebook. Developed and marketed by Sigma® Life Science, the 'What's Your Favorite Gene?' application is the first and currently only application of its kind available on Facebook, and provides a platform that can enable scientists and researchers to network with each other and facilitate discussion based on their favorite genes, identifiable via gene functionality and biological pathways.

19 Nov 2009

New mathematical model may hasten drug development for Parkinson's Disease

Australian scientists have significantly advanced our understanding of dopamine release from nerve cells, findings that should speed the development of more effective drugs for treating Parkinson's Disease.

19 Nov 2009

Anacor Pharmaceuticals commences patient dosing in AN3365 Phase I clinical study

Anacor Pharmaceuticals today announced that it has dosed the first patient in a Phase I clinical study for AN3365, a novel boron-based, small-molecule drug candidate in development for the treatment of hospital infections caused by Gram-negative bacteria. The study will evaluate the safety, tolerability and pharmacokinetics of AN3365 in healthy volunteers.

17 Nov 2009

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing.

17 Nov 2009

Agilent Technologies acquires MassCode Tag technology from Eurofins MWG Operon

Agilent Technologies Inc. today announced it has purchased the MassCode Tag technology from Eurofins MWG Operon, a division of Eurofins. The purchase includes the MassCode trademarks and intellectual property, including four families of patents.

17 Nov 2009

Fate Therapeutics announces the completion of $30 million Series B financing

Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.

16 Nov 2009

CSHL solves the structure of the zinc-bound ATD domain of the NMDA receptor NR2B subunit

A team of scientists at Cold Spring Harbor Laboratory (CSHL) reports on Thursday their success in solving the molecular structure of a key portion of a cellular receptor implicated in Alzheimer's, Parkinson's, and other serious illnesses.

13 Nov 2009

Small Molecules News and Research

Publication validates company's structure-based approach for addressing undruggable targets

Response Biomedical receives USPTO Notice of Allowance for its “Sensitive Immunochromatographic Assay”

Modulating PN aggregase pathway may offer hope for Alzheimer’s disease

Molecular Partners closes its CHF 46 million Series B equity investment round

Winners of the 2010 ASBMB-Merck Award

Discovery of new compounds may dispel cravings of methamphetamine and cocaine addiction

TMZ and small molecule combination appears to lower tumor resistance

Study: Genetic variations in miRNA pathway may be used to predict secondary tumor in head and neck cancer patients

SU2C awards $9.68 million to support high-risk cancer research

TGen scientists win $1,000 prize for best scientific paper presented at BIBM09

Galapagos' multiple milestone achievement triggers cash payment of EUR 10.2 million

New technology developed to rapidly identify compounds for the treatment of heart failure

ScinoPharm receives Potent Compound Safety Certification from SafeBridge Consultants

Unique life science-focused application for social media site launched

New mathematical model may hasten drug development for Parkinson's Disease

Anacor Pharmaceuticals commences patient dosing in AN3365 Phase I clinical study

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

Agilent Technologies acquires MassCode Tag technology from Eurofins MWG Operon

Fate Therapeutics announces the completion of $30 million Series B financing

CSHL solves the structure of the zinc-bound ATD domain of the NMDA receptor NR2B subunit

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News